EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial

Kathryn Cardoza iD, Amy Kang iD, Brendan Smyth iD, Tae Won Yi, Carol Pollock, Rajiv Agarwal iD, George Bakris, David M Charytan iD, Dick de Zeeuw, David C Wheeler, Hong Zhang, Christopher P Cannon und 4 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15685 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Kathryn Cardoza und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cedars-Sinai Medical Center, California, Los Angeles, USA. Hauptthemen laut MEDLINE: Canagliflozin, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Janssen Research and Development Funded the CREDENCE Trial, Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To explore the effect of canagliflozin on kidney and cardiovascular events and safety outcomes in individuals with type 2 diabetes and chronic kidney disease across geographic regions and racial groups. Materials and Methods A stratified Cox proportional hazards model was used to assess efficacy and safety outcomes by geographic region and racial group. The primary composite outcome was a composite of end‐stage kidney disease (ESKD), doubling of the serum creatinine (SCr) level, or death from kidney or cardiovascular causes. Secondary outcomes included: (i) cardiovascular death or heart failure (HF) hospitalization; (ii) cardiovascular death, myocardial infarction (MI) or stroke; (iii) HF hospitalization; (iv) doubling of the SCr level, ESKD or kidney death; (v) cardiovascular death; (vi) all‐cause death; and (vii) cardiovascular death, MI, stroke, or hospitalization for HF or for unstable angina.

Results

The 4401 patients were divided into six geographic region subgroups: North America ( n = 1182, 27%), Central and South America ( n = 941, 21%), Eastern Europe ( n = 947, 21%), Western Europe ( n = 421, 10%), Asia ( n = 749, 17%) and Other ( n = 161, 4%). The analyses included four racial groups: White ( n = 2931, 67%), Black or African American ( n = 224, 5%), Asian ( n = 877, 20%) and Other ( n = 369, 8%). Canagliflozin reduced the relative risk of the primary composite outcome in the overall trial by 30% (hazard ratio 0.70, 95% confidence interval 0.59‐0.82; P = 0.00001). Across geographic regions and racial groups, canagliflozin consistently reduced the primary composite endpoint without evidence of heterogeneity (interaction P values of 0.39 and 0.91, respectively) or significant safety outcome differences.

Conclusions

Canagliflozin reduces the risk of kidney and cardiovascular events similarly across geographic regions and racial groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsCardiovascular DiseasesHumansMaleFemaleMiddle AgedAgedDiabetic NephropathiesRenal Insufficiency, ChronicHospitalizationKidney Failure, ChronicEuropeTreatment OutcomeNorth AmericaProportional Hazards Models

Stichwörter der Autor:innen

SGLT2 inhibitorcanagliflozincardiovascular diseasediabetic nephropathyheart failuretype 2 diabetes

Substanzen

CanagliflozinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Cedars-Sinai Medical Center, California, Los Angeles, USA.
  • Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
  • The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia.
  • Department of Renal Medicine, St George Hospital, Kogarah, New South Wales, Australia.
  • NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.

ORCID-Profile: Kathryn Cardoza, Amy Kang, Brendan Smyth, Rajiv Agarwal, David M Charytan, Clare Arnott, Adeera Levin

Förderung

  • Janssen Research and Development Funded the CREDENCE Trial
  • Janssen Research and Development

Zitieren

APA

Cardoza, K., Kang, A., Smyth, B., Yi, T. W., Pollock, C., Agarwal, R., Bakris, G., Charytan, D. M., de Zeeuw, D., Wheeler, D. C., Zhang, H., Cannon, C. P., Perkovic, V., Arnott, C., Levin, A., & Mahaffey, K. W. (2024). Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15685

Vancouver

Cardoza K, Kang A, Smyth B, Yi TW, Pollock C, Agarwal R, et al. Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15685

BibTeX
@article{Cardoza2024,
  author = {Cardoza, Kathryn and Kang, Amy and Smyth, Brendan and Yi, Tae Won and Pollock, Carol and Agarwal, Rajiv and Bakris, George and Charytan, David M and de Zeeuw, Dick and Wheeler, David C and Zhang, Hong and Cannon, Christopher P and Perkovic, Vlado and Arnott, Clare and Levin, Adeera and Mahaffey, Kenneth W},
  title = {Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15685}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche